KX2-391

Phase 2Small molecule

KKinex Pharmaceuticals Inc.

KX2-391 is one of 86 small molecule programs targeting Prostate Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate CancerActive, not recruiting

Acute Myeloid LeukemiaActive, not recruiting

Actinic KeratosisActive, not recruiting

Prostate CancerPhase 2

Active, not recruiting

Acute Myeloid LeukemiaPhase 1

Active, not recruiting

Actinic KeratosisPhase 1

Active, not recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Novantrone

Pfizer

Preclinical

5 2

Mekinist

Novartis

Preclinical

3 3

KX2-391

KKinex Pharmaceuticals Inc.

Phase 2

1 4

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 5

Viagra

VViatris Specialty LLC

Preclinical

1 6

Duragesic

CCephalon

Preclinical

1 7

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 8

Prednisone/prednisolone

Roche

Preclinical

3 9

Triptorelin Pamoate

Ipsen

Preclinical

2 10

Osmitrol

BB. Braun Medical Inc.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Prostate Cancer1 trial

Safety and Efficacy Study of KX2-391 for Treatment of Bone-Metastatic, Castration-Resistant Prostate Cancer

Completed·AAthenex, Inc.·Phase 2·NCT01074138·31 enrolled

Actinic Keratosis1 trial

Ph 1, Single-Center, Safety, Tolerability & Pharmacokinetic Study of KX2 391 Ointment in Subj. w Actinic Keratosis

Completed·AAthenex, Inc.·Phase 1·NCT02337205·29 enrolled

Advanced Malignancies1 trial

Evaluation of KX2-391 in Patients With Advanced Malignancies

Completed·AAthenex, Inc.·Phase 1·NCT00658970·50 enrolled

Acute Myeloid Leukemia1 trial

Evaluation of KX2-391 in Elderly Subjects With Acute Myeloid Leukemia (AML)

Completed·KKinex Pharmaceuticals Inc.·Phase 1·NCT01397799·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for KX2-391. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — KX2-391 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for KX2-391. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Kinex Pharmaceuticals Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: KKinex Pharmaceuticals Inc.

KX2-391

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Prostate Cancer1 trial

Actinic Keratosis1 trial

Advanced Malignancies1 trial

Acute Myeloid Leukemia1 trial

References

Drug Info

Quick Facts

Related News